GuiZhou SanLi Pharmaceutical Co.,Ltd
SHH: 603439.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Qianfan Zhang
- Employees
- 2,852
- Headquarters
- Anshun, China
- IPO year
- 2020
- Market cap
- CN¥4.5B
- Website
- https://www.gz-sanli.com
Loading 603439…
Loading profile data…Frequently asked questions about 603439
What does GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) do?
GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company w...
Where does 603439.SS trade?
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) trades on the Shanghai Stock Exchange.
What sector is 603439.SS in?
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of GuiZhou SanLi Pharmaceutical Co.,Ltd?
Qianfan Zhang is the chief executive officer of GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS).
Where is GuiZhou SanLi Pharmaceutical Co.,Ltd headquartered?
GuiZhou SanLi Pharmaceutical Co.,Ltd is headquartered in China.
Does 603439.SS pay a dividend?
Yes — GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) paid a trailing twelve-month dividend of CNY 0.34 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 603439.SS go public?
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) completed its initial public offering in 2020.